I N T R O D U C T I O N
Alport syndrome (AS) is a hereditary, progressive kidney disease caused by mutation of one of the type IV collagen genes (COL4A3, COL4A4, COL4A5), which are components of the glomerular basement membrane (GBM). Mutation of the COL4A5 gene, located on the X chromosome, constitutes $85% of AS patients, and these patients develop end-stage renal disease (ESRD) in 20-30 years [1] . Currently, renin-angiotensin-aldosterone system (RAAS) inhibitor is used to treat AS patients [2] . Although renin inhibitors and aldosterone blockers can delay dialysis or renal transplantation, patients eventually develop ESRD [3, 4] . Therefore, more effective treatment for AS is needed [5] . Understanding the molecular mechanism of progressive kidney failure is a crucial step to developing better treatment. AS exhibits various phenotypes, including proteinuria, inflammation and fibrosis, which are similar to other chronic kidney diseases (CKDs) [6] . The upregulation of pro-inflammatory cytokines and Nephrol Dial Transplant (2018) 33: 214-223 doi: 10.1093/ndt/gfx246 Advance Access publication 17 August 2017 pro-fibrotic genes causes renal injury and fibrosis and eventually leads to ESRD [2] . However, the key molecules and cell signaling pathways that regulate the progression of kidney dysfunction in AS remains to be elucidated.
Signal transducer and activator of transcription 3 (STAT3) has been reported to mediate various cellular functions such as cell proliferation and survival [7] . STAT3 induces the expression of multiple target genes such as transforming growth factor beta (TGF-b) and matrix metalloproteinases (MMPs), which are known to promote renal fibrosis and dysfunction [8, 9] . STAT3 is activated by various mediators, including interleukin-6 (IL-6) and epidermal growth factor (EGF) [10] . A previous study showed that STAT3 is activated in several renal diseases, and its activation contributes to the progression of CKD [11] . However, the functional role of STAT3 in AS progression has not yet been investigated. In the present study we showed that STAT3 signaling is activated in AS mice kidneys and glomeruli. To evaluate the role of STAT3 in the progression of AS, we treated AS mice with the STAT3 inhibitor stattic, which is a small molecule that inhibits STAT3 activation and dimerization [12] . Interestingly, pharmacological inhibition of STAT3 significantly ameliorated several AS phenotypes, such as renal dysfunction, inflammation and fibrosis. Our findings reveal STAT3 as an exacerbating factor in AS progression and provide insights into potential therapeutic approaches for the treatment of AS.
M A T E R I A L S A N D M E T H O D S

Animals and in vivo treatment
An X-linked AS mouse model (Col4a5tm1Yseg G5X mutant) was described previously [13] . These mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). In some experiments, reproductive techniques established by the Center for Animal Resources and Development (CARD, Kumamoto University) were applied to efficiently produce an optimal number of mice with stably exhibiting phenotypes [14] . Agematched wild-type (WT) C57BL/6 mice were used for experiments as controls to compare with AS mice. Six-week-old WT and AS mice were treated with stattic (10 mg/kg, i.p. three times per week for 10 weeks). Male mice were used in all experiments to eliminate sex differences due to sex-linked inheritance of the Col4a5tm1Yseg G5X mutation. Stattic was purchased from Cayman Chemical (Ann Arbor, MI, USA). All animal experiments were approved by the Animal Care and Use Committee of Kumamoto University (#A28-059).
Proteinuria score
Urine collection was performed using a metabolic cage (As One, Osaka, Japan) for 24 h once every 2 weeks. Urinary protein and creatinine were measured by the Bradford method (BioRad Laboratories, Hercules, CA, USA) and Jaffe's method (Wako Pure Chemical Industries, Tokyo, Japan), respectively. Urinary protein concentration was normalized with urinary creatinine concentration and presented as a proteinuria score.
Blood urea nitrogen and serum creatinine
Mouse blood was obtained from the abdominal aorta. Fresh blood samples were centrifuged at 800 g, 4 C, for 15 min, and blood plasma was collected. Blood urea nitrogen (BUN) of plasma was measured using Fuji Dri Chem BUN PIII (Fujifilm, Tokyo, Japan). Serum creatinine was measured by Jaffe's method (Wako Pure Chemical Industries). The analysis of samples was carried out according to the manufacturer's recommended protocol.
Immunohistochemistry and immunofluorescence
For immunohistochemistry, kidney tissues were immersed consecutively in 4% paraformaldehyde and 75% ethanol and embedded in paraffin. The de-paraffinization step was done using xylene and ethanol. Antigen activation was performed using Dako real-target retrieval solution (Dako, Kyoto, Japan) at 98 C for 40 min, then samples were incubated at room temperature for 20 min. After blocking for 30 min, samples were reacted with STAT3 (C6198; Sigma-Aldrich, St Louis, MO, USA) or F4/80 (ab6640; Abcam, Cambridge, UK) antibodies. Histofine Simple stain (Nichirei Biosciences, Tokyo, Japan) was used for secondary antibody reactions. After a phosphate-buffered saline wash, a diaminobenzidene reaction was performed for 1-10 min. Slides were stained with hematoxylin for 90 s. Immunoblots were evaluated using Bio-Revo imaging and analysis software (Keyence, Osaka, Japan). For immunofluorescence, samples were reacted with a-SMA-Cy3 primary antibody diluted at 1:200. a-SMA-positive areas were analyzed using Bio-Revo imaging and analysis software (Keyence).
Evaluation of glomerular injury score and tubulointerstitial fibrosis
For renal histology, AS and WT mouse kidneys were fixed in 10% formalin and embedded in paraffin for Masson's trichrome (MT) and periodic acid-Schiff (PAS) staining. Tissue blocks were sliced at 4-lm thickness. The glomerular injury score and tubulointerstitial fibrosis score were assessed as described previously [15] . Briefly, for assessment of glomerular injury, renal sections were stained with PAS. To determine the glomerular injury score, >100 PAS-stained random glomeruli per mouse (n ¼ 3-8 mice) were examined and scored from 0 to 4 (0, no lesion; 1, expansion of mesangial area; 2, expansion of Bowman's epithelial cells and adhesion of glomeruli and Bowman's capsule; 3, sclerotic area in 50-75% of glomerulus; 4, sclerotic area in 75-100% of glomerulus). Double-blind scoring was performed and values were computed and presented in a graph as a percentage. For tubulointerstitial fibrosis, MT-stained kidneys were evaluated using Bio-Revo imaging and analysis software (Keyence). The MT-stained area versus unstained area was calculated and presented as a percentage of the fibrotic region.
Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis
Quantitative RT-PCR (qRT-PCR) was carried out as described previously using RNA isolated from kidney tissues and glomeruli. RT and PCR amplifications were performed as described previously [16] . The sequences of primers used for qRT-PCR are shown in Table 1 .
Western blotting analysis
Isolated whole kidneys were lysed in radio immunoprecipitation (RIPA) buffer [50 mM Tris-HCl, 150 mM NaCl, 1 mg/ml sodium deoxycholate and 1% NP-40, containing 1% protease inhibitor cocktail (Sigma-Aldrich), 2 mM sodium vanadate and 100 mM sodium fluoride]. Isolation of glomeruli was previously described [17] . Protein lysates from whole kidneys and glomeruli were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blot analysis. Immunoblots were probed with antibodies for phosphorylated STAT3, phosphorylated Smad1/5/8 (#9145 and #95115, respectively; Cell Signaling Technology, Danvers, MA, USA), TGF-b and STAT3 (sc-130348 and sc-482; Santa Cruz Biotechnologies, Dallas, TX, USA) followed by their respective horseradish peroxidase-conjugated secondary antibodies. c-Tubulin (sc-7396; Santa Cruz Biotechnologies Inc.) and Hsc70 antibodies (SPA-815; Enzo Life Science, Farmingdale, NY, USA) were used as loading controls. SuperSignal WestPico chemiluminescence substrate (Thermo Fisher Scientific, Waltham, MA, USA) was used for visualizing the blots.
Cell culture of human podocyte cell line and ciliary neurotrophic factor (CNTF) treatment
Cell culture of the human podocyte cell line was previously described [18, 19] . The human podocyte cell line was treated with recombinant human CNTF (0.1 or 0.5 mg/ml; 257-NT/CF, R&D Systems, Minneapolis, MN, USA).
Statistical analysis
All data are presented as mean 6 SE. The significance of the difference between two groups was assessed using Student's unpaired two-tailed t-test. For three-group comparisons we used analysis of variance (ANOVA) with the Tukey-Kramer test. P-values <0.05 were considered to be statistically significant.
R E S U L T S
STAT3 signaling is activated in AS mice kidneys
To determine whether STAT3 signaling is activated in AS mice, we first checked the expression of STAT3. We found that phosphorylated STAT3 and total STAT3 were significantly elevated in AS mice kidneys ( Figure 1A-D) . Moreover, an increase in the protein levels of basal and phosphorylated STAT3 was also observed in AS glomeruli ( Figure  1E-H) . Immunostaining of kidney sections revealed higher expression of STAT3 in AS mice compared with WT ( Figure  1I ). To confirm the activation of STAT3 signaling, we determined the mRNA level of Il-6, a target gene of STAT3, and Socs3, a negative regulator of STAT3 signaling, which is induced by STAT3 activation [20, 21] . Il-6 and Socs3 expression levels were increased in the kidneys and glomeruli of AS mice compared with WT mice ( Figure 1J and K). We next examined the mRNA expression of Stat3 to determine if Stat3 upregulation occurred at the transcriptional level. Stat3 mRNA expression was increased, albeit slightly, in AS mice kidneys and had the tendency to increase in the glomeruli ( Figure 1J and K). Upregulation of Tgf-b and Mmp9 exacerbates AS pathologies. Interestingly, in 12-week-old AS mice, while STAT3 activation was observed, Tgf-b and Mmp9 expression levels were not significantly elevated ( Figure 1J and K). These data indicated that STAT3 expression and signaling were induced in AS mouse kidney and glomerulus.
Stattic ameliorated the renal dysfunction in AS mice
To determine the contribution of STAT3 on AS pathology, we treated AS mice with the STAT3 inhibitor stattic. Stattic (10 mg/kg body weight) was intraperitoneally administered three times a week (Figure 2A ) as described in a previous study [22] . Stattic treatment did not affect body weight, urine volume or food intake (Supplementary data, Figure 1A -C), indicating that stattic has no overt toxic side effects. Next, we monitored proteinuria, which is an indicator for progression of kidney failure as well as a detrimental factor of kidney function [23] . Stattic treatment ameliorated the progressive proteinuria, especially in 14-to 16-week-old AS mice, while proteinuria worsened in vehicle-treated AS mice ( Figure 2B ). We next evaluated renal function parameters such as BUN and serum creatinine. Stattic decreased the AS-induced upregulation of BUN and serum creatinine (Figure 2C and D) . We also checked the mRNA expression of renal injury markers such as Lcn2 and Kim-1, which are induced during renal dysfunction [24] . We found that stattic significantly suppressed the gene expression levels of renal injury markers in AS mice ( Figure 2E ). Taken   Table 1 
Gene
Sense Antisense 
STAT3 inhibition suppressed glomerular injury in AS mice
We investigated the effect of STAT3 inhibition on glomerular injury, which is one of the characteristics of AS. In AS mice, PAS-stained glomeruli with a severity score of 0 were fewer than in WT mice. On the other hand, glomeruli with a high severity score (3 or 4) were increased in AS mice. Interestingly, glomeruli with a severity score of 3 (high severity) were statistically decreased in stattic-treated AS mice compared with vehicletreated AS mice ( Figure 3A and B). STAT3 signaling is activated in the kidneys and glomeruli of AS mice. Protein lysates from (A) whole kidneys or (E) glomeruli were isolated from WT or AS mice in the middle stage of AS (12 weeks) and immunoblotted to detect p-STAT3, total STAT3, c-tubulin and Hsc70. c-Tubulin and Hsc70 were used as loading controls. The relative amount of p-STAT3 and STAT3 in the kidneys (B-D) or glomeruli (F-H) was quantified and normalized to the indicated proteins. (I) Glomerular sections from WT and AS mice were immunostained to detect STAT3. Total RNA was isolated from (J) kidney tissues or (K) glomeruli of 12-week-old mice. Quantitative RT-PCR was performed to evaluate the expression of STAT3-related genes. Bars indicate the mean 6SE (n ¼ 3-4). *P < 0.05; **P < 0.01 versus WT. 
S T A T 3 i n h i b i t i o n a t t e n u a t e s p r o g r e s s i v e p h e n o t y p e s o f
STAT3 inhibition suppressed renal inflammation in AS mice
Along with glomerular injury, renal inflammation also characterizes AS, so we investigated the effect of stattic on this phenotype. Inflammatory cell infiltration was mostly observed in vehicle-treated AS mice, but was reduced by treatment with stattic ( Figure 4A, black arrowheads) . We next checked the F4/80-positive area, which is a macrophage marker. We found that stattic ameliorated macrophage infiltration ( Figure 4A and B) . Moreover, the expression levels of pro-inflammatory cytokines Il-6 and KC/Il-8 as well was Stat3 and Socs3 were induced in AS mice. But treatment of AS mice with stattic resulted in a decrease in the expression level of these genes ( Figure 4C ).
STAT3 inhibition suppressed renal fibrosis in AS mice
We next assessed renal fibrosis, a critical step in end-stage renal failure of AS. We stained kidney sections with MT and found that stattic treatment reduced the fibrotic region in AS kidneys compared with the vehicle-treated AS group (Figure . Moreover, the expression of a-SMA, a marker of fibrosis, was elevated in AS kidney, but this was decreased in the stattic-treated AS group (Figure 5A and C) . We also evaluated the effect of stattic on the expression of Mmp9 and profibrotic genes (Col1a1, Tgf-b, a-Sma). These genes were previously reported to be upregulated and promote the progression of renal dysfunction in AS mice [15] . As expected, the expression of Mmp9 and pro-fibrotic genes was increased in vehicle-treated AS mice, but stattic treatment significantly suppressed AS-induced gene expression ( Figure 5D and E). The reduction in the a-Sma mRNA level is consistent with the decrease in a-SMA staining shown above. STAT3 acts as a transcriptional activator of its target genes, such as Tgf-b, a master regulator of fibrosis [20] . The decrease in Stat3 and Tgf-b in stattic-treated AS mice, albeit slightly in the latter, is congruent with the reduction of type IV collagen expression (C) The a-SMA-positive area was quantified based on the immunostained images using Bio-Revo imaging and analysis. Bars indicate the mean 6 SE (n ¼ 3-10). Total RNA was isolated from kidney tissues of 16-week-old mice. Quantitative RT-PCR was performed to evaluate the expression of (D)Mmp9 and (E) pro-fibrotic genes. Bars indicate the mean 6 SE (n ¼ 4-10). *P < 0.05; **P < 0.01.
| | | | | | | |
in AS mice treated with stattic (Supplementary data, Figure  2A and B).
Because stattic treatment ameliorated fibrosis in AS mice, we investigated how stattic improves fibrosis. The TGF-b protein level was increased in AS kidney tissues, but stattic treatment significantly suppressed the AS-induced upregulation of TGF-b ( Figure 6A and B) , which is consistent with the mRNA expression shown in Figure 5E . These data indicate that stattic suppresses TGF-b protein expression via transcriptional regulation of Tgf-b mRNA. We also focused on Smad1/5/8, which are negative regulators of TGF-b signaling [25] . It was previously reported that STAT3 activation induces the downregulation of phosphorylated Smad1/5/8 [26] . Here we found that stattic treatment inhibited the AS-induced downregulation of p-Smad1/5/8 in AS mice kidneys ( Figure 6A and C) . Lastly, consistent with stattic being an inhibitor of STAT3 signaling, we found that stattic treatment significantly suppressed the AS-induced upregulation of phosphorylated STAT3 (p-STAT3; Figure 6A and D-F). Taken together, our data indicate that STAT3 inhibition suppresses the fibrotic signaling molecule TGF-b and activates p-Smad1/5/8, the antifibrotic signaling molecule, resulting in reduced renal fibrosis.
D I S C U S S I O N
A number of studies have implicated a role of the JAK/STAT signaling pathway via STAT3 in renal fibrosis using experimental models of renal diseases, such as in experimental nephrotic syndrome and unilateral ureteral obstruction (UUO) models [11, 27] . Other works also showed the involvement of STAT3 in polycystic kidney disease and diabetic glomerulopathy [28, 29] . These findings highlighted a therapeutic potential of targeting STAT3 in CKD. In the present study, we first provide evidence that STAT3 is activated in the kidneys of an X-linked AS (XLAS) mouse model. Furthermore, the pharmacological suppression of activated STAT3 restrained the progression of proteinuria, improved renal function in AS mice and suppressed AS disease-associated gene expression such as renal injury markers, pro-inflammatory cytokines and pro-fibrotic genes. These results indicated that STAT3 has an important role in accelerating the inflammatory and fibrotic phenotypes in AS mice. Moreover, we found that STAT3 signaling was upregulated in the kidneys and glomeruli of 12-week-old AS mice, while the expression levels of Tgf-b and Mmp9 were not significantly elevated, which suggested that STAT3 signaling was activated prior to the increase of other exacerbating factors ( Figure  1J and K). Therefore, STAT3 activation could be involved in the initiation of microinflammation in the glomerulus, which is the likely origin in AS nephritis.
STAT3 was clearly activated in the kidneys and glomeruli of middle-stage (12 weeks) AS mice (Figure 1 ). Less clear is the molecular underpinning of STAT3 activation. Our previous and recent works have demonstrated that various mediators of STAT3 signaling are upregulated in AS mice kidneys such as Il-6 and Cntf [15, 17] . Moreover, we found that CNTF is upregulated in the glomeruli of AS mice and recombinant CNTF also induced STAT3 activation in the human podocyte cell line (Supplementary data, Figure 3A and B). These molecules could be partly responsible for the activation of STAT3 signaling in AS, especially Il-6, which is induced in AS kidneys as early as 8 weeks [15] . In addition to these soluble factors, we recently reported that the tumor suppressor p53 has a protective role against nephritis in XLAS, and notably, p53 expression was remarkably reduced in the glomeruli of AS mice [17] . p53 is known to suppress STAT3 activation, and reciprocally, STAT3 negatively regulates p53 expression [30] [31] [32] . Notably, we observed that phosphorylated STAT3 expression had the tendency to increase in AS mice kidneys with podocyte-specific deletion of p53 (Pod-p53 KO AS; Supplementary data, Figure 3C -F). Based on these findings, it is logical to conjecture that the inflammatory milieu of AS kidneys, wherein IL-6 and various cytokines are upregulated, activates STAT3 signaling, which adversely affects p53 expression. The lack of a modulatory factor such as p53 could result in constitutive activation of STAT3 signaling and the vicious loop of STAT3/inflammation/profibrotic factors [17] .
That treatment with stattic increased the antifibrotic molecules Smad1/5/8 and decreased renal fibrosis attests to the important contribution of STAT3 in renal fibrosis and dysfunction. Further studies will elucidate the mechanism of STAT3 activation in AS and could help to further understand AS etiology in the context of dysregulated signal transduction. In the current study we only performed a few weeks of treatment with stattic to investigate the impact of stattic on renal dysfunction in AS mice, and saw some positive effects. A recent study showed that Pentraxin-2 (PTX-2) suppressed the AS pathologies and improved the lifespan in AS mice [33] . The positive effects of PTX-2 on AS pathologies are similar to STAT3 inhibition. Therefore, survival studies of AS mice treated with stattic could clarify the effects of STAT3 inhibition on the amelioration of AS. From a clinical standpoint, although RAAS inhibitors are mainly used in AS therapy and are effective to some extent, most patients eventually develop ESRD. Investigations of the molecular mechanistic details of AS progression could provide insights into novel avenues of radical cure for AS.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http://ndt.oxfordjour nals.org.
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